Logo Logo
Help
Contact
Switch Language to German
Pleyer, Uwe; Klamann, Matthias; Laurent, Thierry-Jens; Mänz, Martin; Hazirolan, Dicle; Winterhalter, Sibylle; Thurau, Stephan R. (2014): Fast and Successful Management of Intraocular Inflammation with a Single Intravitreal Dexamethasone Implant. In: Ophthalmologica, Vol. 232: pp. 223-229
[img]
Preview
174kB

Abstract

Purpose: To investigate the efficacy and safety of a single dexamethasone intravitreal implant (Ozurdex\circledR, 700 µg). Methods: In this prospective noncomparative case series, 84 patients (54 females) received a dexamethasone intravitreal implant. At weeks 4, 12 and 24 after the injection, vitreous haze, macular thickness and best corrected visual acuity (BCVA) were assessed and adverse events reported. Results: Clearance of vitreous haze could be achieved after 4 weeks in 61% of all eyes (p \textless 0.001) and remained significant until week 24 (p \textless 0.001). This was paralleled by a reduction of central retinal thickness after 4 (p \textless 0.001), 12 (p \textless 0.001) and 24 weeks (p \textless 0.006). Significant and fast improvement of BCVA was already achieved after 4 weeks (p \textless 0.001) but vanished by week 24. Intraocular pressure reached \geq35 mm Hg in 3 eyes and was significantly more frequent in intermediate uveitis compared to posterior uveitis (p \textless 0.016). Conclusions: The dexamethasone implant is effective in controlling intraocular posterior segment inflammation and reduces central retinal thickness fast and effectively. © 2014 S. Karger AG, Basel.